BHC - Bausch Health Companies Inc.
After hours:
| Previous close | 8.19 |
| Open | 8.11 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1000 |
| Day's range | 7.99 - 8.24 |
| 52-week range | 4.00 - 10.23 |
| Volume | |
| Avg. volume | 3,675,526 |
| Market cap | 3.008B |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 10 Nov 2010 |
| 1y target est | 13.10 |
ZacksBausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
Simply Wall St.The 6.3% return this week takes Bausch + Lomb's (NYSE:BLCO) shareholders one-year gains to 18%
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...
Motley FoolWhy Shares of Bausch Health Soared Wednesday
Shares of Bausch Health (NYSE: BHC) were up more than 27% late Wednesday afternoon because the company announced it had received a favorable court ruling affecting one of its leading therapies. The healthcare company announced that the U.S. District Court of Delaware had ruled in its favor in a lawsuit by Bausch wholly owned subsidiary Salix Pharmaceuticals against Norwich Pharmaceuticals.
ZacksBausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
ZacksBausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksBausch Health (BHC) Misses Q1 Earnings and Revenue Estimates
Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksBausch + Lomb (BLCO) Q1 Earnings Lag Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of -28.57% and 3.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksEarnings Preview: Bausch Health (BHC) Q1 Earnings Expected to Decline
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 0.3x Bausch Health Companies Inc. ( NYSE:BHC ) may be sending very bullish...
- Simply Wall St.
Lacklustre Performance Is Driving Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S
With a price-to-sales (or "P/S") ratio of 1.5x Bausch + Lomb Corporation ( NYSE:BLCO ) may be sending very bullish...
ZacksImplied Volatility Surging for Bausch Health (BHC) Stock Options
Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.
- Simply Wall St.
Bausch Health Companies Inc. (NYSE:BHC) On The Verge Of Breaking Even
With the business potentially at an important milestone, we thought we'd take a closer look at Bausch Health Companies...
ZacksBausch Health (BHC) Q4 Earnings and Revenues Top Estimates
Bausch (BHC) delivered earnings and revenue surprises of 10.87% and 3.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksPerion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day
Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.
- Simply Wall St.
Bausch + Lomb Full Year 2022 Earnings: EPS Misses Expectations
Bausch + Lomb ( NYSE:BLCO ) Full Year 2022 Results Key Financial Results Revenue: US$3.77b (flat on FY 2021). Net...
ZacksDrug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.
- Simply Wall St.
Positive week for Bausch Health Companies Inc. (NYSE:BHC) institutional investors who lost 60% over the past year
A look at the shareholders of Bausch Health Companies Inc. ( NYSE:BHC ) can tell us which group is most powerful. With...
ZacksBausch (BHC) Stock Jumps 19.3%: Will It Continue to Soar?
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Simply Wall St.
Bausch + Lomb Corporation's (NYSE:BLCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Bausch + Lomb's (NYSE:BLCO) stock is up by a considerable 12% over the past three months. But the company's key...
- Simply Wall St.
Bausch Health Companies (NYSE:BHC) shareholders are up 19% this past week, but still in the red over the last three years
It's nice to see the Bausch Health Companies Inc. ( NYSE:BHC ) share price up 19% in a week. But the last three years...
ZacksImplied Volatility Surging for Bausch + Lomb (BLCO) Stock Options
Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.
ZacksNew Strong Sell Stocks for December 9th
ACCO, BHC and HOUS have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2022.
ACCESSWIREBausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") has designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb"), as an unrestricted subsidiary of the Company in accordance with the terms of the Company's debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C.
- Simply Wall St.
Is There An Opportunity With Bausch + Lomb Corporation's (NYSE:BLCO) 45% Undervaluation?
How far off is Bausch + Lomb Corporation ( NYSE:BLCO ) from its intrinsic value? Using the most recent financial data...
- Simply Wall St.
Bausch Health Companies Third Quarter 2022 Earnings: EPS Beats Expectations
Bausch Health Companies ( NYSE:BHC ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.05b (down 3.1% from...
